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Abstract
Background: Following mitral valve replacement, surgical closure of paravalvular leaks is usually advised in severely symptomatic
patients and in those requiring blood transfusions for persisting haemolysis. However, the long-term prognosis of less symptomatic patients
or those not needing blood transfusions is unknown. Methods: Between 1987 and 1997, we observed 96 patients with mitral paravalvular
leakage. A paraprosthetic leak was diagnosed after a median time of 119 days (range: 1 day±23 years) after primary mitral valve replacement.
During an average follow-up of 5 years (range: 1±23 years), 50/96 patients were referred for surgical closure. Results: Compared with
patients who received conservative treatment, those referred for surgery had a signi®cantly lower mean preoperative haematocrit (P  0:002)
with a higher proportion of patients being in the NYHA class III/IV (P  0:03). Age, gender, left ventricular function and number and size of
leaks did not differ between the groups. The 30-day postoperative mortality for valve reoperation was 6% (3/50); during follow-up three
further patients died, resulting in an overall mortality rate of 12%. In the group treated conservatively there was a mortality rate of 26% (12/
46). Thus, the actuarial survival for patients referred for surgery was 98, 90 and 88% after 1, 5 and 10 years, compared with 90, 75 and 68%
for patients treated conservatively (long-rank P  0:03). In addition, there was a signi®cant increase in mean haematocrit levels
(P  0:0001) and an improvement in NYHA class III/IV symptoms (P  0:002), vertigo (P  0:001) and fatigue (P  0:001) after surgery.
Conclusions: Following mitral valve replacement, a more aggressive surgical treatment is recommended for patients with paraprosthetic
leaks. Surgery should be offered to less symptomatic patients, as well as those not requiring blood transfusion. q 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Cardiac valve replacement is a well-established and safe
procedure with a low mortality rate. It confers considerable
bene®ts in patients with chronic valvular disease in terms of
improved cardiac physiological function and increased
survival. The procedure is not, however, free from compli-
cations, such as thromboembolism, anticoagulant-related
haemorrhage, prosthetic valve endocarditis and valve
dysfunction.
Valve dysfunction may be caused by a variety of factors,
including infection, tissue failure associated with bioprosth-
eses or mechanical problems. Recurrent regurgitation,
which may be due to a paraprosthetic leak, is a clinical
manifestation of valve dysfunction and may itself arise
from a variety of causes. Surgical closure of paravalvular
leaks is usually advised in severely symptomatic patients
and in those requiring blood transfusions for persisting
haemolysis. However, the long-term prognosis of less
symptomatic patients, or those not needing blood transfu-
sions, is unknown.
2. Patients and methods
A new holosystolic regurgitant murmur is an indication of
the presence of a paravalvular leak. The gold standard
procedure for diagnosis of a paravalvular leak in the mitral
position is echocardiography [1±3]. Optimal visualization
of mitral jets, and the absence of acoustic shadowing from
prosthetic material in the left atrium, account for the
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increasing use of trans-oesophageal echocardiography in
evaluating mitral prostheses. Nowadays, however, the use
of be-lea¯et mechanical prostheses means that the diagnosis
is no longer simple. These prostheses characteristically have
two to four small, low turbulence jets originating from
within the valve ring. Regurgitation is considered to be
paravalvular if a turbulent eccentric jet originates outside
the prosthetic sewing ring, or a paravalvular gab is visua-
lized between the annulus and the sewing ring. The pathol-
ogy of the mitral valve is summarized in Fig. 1.
Between 1987 and 1997, 618 mitral valve replacements
were performed at the University Hospital in Zurich. In this
series, we observed 82 paravalvular leaks in 75 patients
(primary leaks in 75 patients in 598 operations and seven
re-leaks in 20 reoperations). A further 21 patients with
mitral paravalvular leak, in whom primary mitral valve
replacement was performed either before 1987 or at another
institution, were surgically treated during the same observa-
tion period. In total, 49/96 patients (51%) were male and 47/
96 (49%) were female. The mean age at the time of the
mitral valve replacement that caused the leak was 54.6
years (^13.4; range 25±80 years).
All patients underwent standard cardiopulmonary bypass
with arterial and bicaval (45%) or atrial (55%) cannulation.
Cardioplegia and systemic hypothermia were used to
protect the myocardium in 68% of patients, whilst in the
remaining 32%, surgery was performed in ventricular ®bril-
lation. The surgical technique employed for primary mitral
valve replacement included complete excision of valve
tissue in 69% and conservation of the posterior lea¯et in
31%. The mitral prosthesis was customarily secured by
interrupted sutures of 2/0 Ticron. A mechanical prosthesis
was used in 97% of cases. Patients with mechanical pros-
theses received anticoagulant treatment with warfarin from
the ®rst postoperative day. All patients received antibiotics
at induction of anaesthesia and post-operatively for 24 h;
antibiotic treatment was prolonged in some patients where
clinically indicated.
Records of all patients with mitral paravalvular leak were
reviewed. All patients who were still alive were contacted
and asked to complete a questionnaire with the help of their
doctor (in particular for the echocardiography data). The
total follow-up period covered 517 years, with a mean
observation time of 5.17 years. A total of 18/96 (19%)
patients died during the follow-up period; of the remaining
78 patients, follow-up was completed in 72 (92%).
2.1. Statistical analyses
Distribution for all relevant variables was reported either
as a percentage or as the mean ^ standard deviation. Statis-
tical analyses were performed using the SPSS 6.1 program.
The effects of nominal risk factors were evaluated with the
Chi-quadrant test. The effects of independent variables were
evaluated with the Mann±Whitney and Kruskal±Wallis
tests; continuous variables were univariately evaluated
with the Wilcoxon-signed rank test. Differences between
groups were analyzed using the log rank test and Cox±
regression was used to detect independent risk factors.
Signi®cance was assumed at a P-level of , 0.05.
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Fig. 1. Pathology of mitral valve disease.
3. Results
The incidence of primary paravalvular leak after mitral
valve replacement in patients who underwent surgery
during the same time period at the same institution was
12.5% (75/598). As shown in Table 1, the incidence of
paravalvular leaks differed between subgroups of patients
with different underlying diseases; the risk was highest after
mitral valve replacement for mitral valve endocarditis and
re-leak.
Symptoms at the time of diagnosis of paravalvular leak
after mitral valve replacement were major fatigue (67% of
patients), vertigo (55%) and NYHA class III/IV dyspnoea
(38%). Only 12.5% of patients had heart failure.
The interval between mitral valve replacement and diag-
nosis of a paravalvular leak was 798 days (^1674 days;
median 119 days). The longest period between mitral
valve replacement and the diagnosis of paravalvular leak
was 23 years. Fig. 2 shows the number of diagnoses during
different time intervals after mitral valve replacement; 74%
of paravalvular leaks were diagnosed during the ®rst post-
operative year and 22% during the ®rst postoperative week.
Signi®cant predictors for a shorter interval between mitral
valve replacement and diagnosis of paravalvular leak were
older age (P  0:01), surgeons with less experience of
mitral valve prostheses (P  0:019), larger leaks
(P  0:023) and extended haemolysis (P  0:001).
The 96 patients were divided in two groups; 46 were
treated conservatively and 50 were treated surgically. The
decision to reoperate was mainly in¯uenced by the cardiol-
ogists' referral practice. Their decision to refer the patient to
the surgeons was based on the normal indications for
surgery. They could, upon follow-up examination, transfer
any of the patients to the surgical group. Comparison of the
baseline data for these two groups revealed signi®cant
differences in terms of NYHA class III/IV symptoms,
haematocrit and lactate dehydrogenase (LDH) levels
(Table 2). Highly symptomatic patients were more
frequently treated surgically; 80% of the patients with
NYHA class III symptoms and 67% with NYHA class IV
symptoms were included in the surgical group (Fig. 3). The
surgically treated patients also had more marked haemolysis
(Fig. 4) resulting in a signi®cantly higher LDH level and a
signi®cantly lower haematocrit.
The early mortality in the surgical group was 6% (n  3).
During the whole observation period there were 12 deaths in
the conservative group, three of which were valve-related,
resulting in a mortality rate of 26%. In the surgically treated
patients, there were six deaths in total, resulting in an overall
mortality of 12%. Statistical analysis of survival using the
Cox±regression model (Fig. 4) revealed a signi®cantly
better survival after surgery (P  0:035).
Surgery not only improved survival, but also the symp-
toms. Table 3 shows the signi®cant improvement in symp-
toms (NYHA class III/IV, P  0:002; vertigo, P  0:001;
and fatigue, P  0:001) and haematocrit (P  0:001) at
follow-up in surgically treated patients. Moreover, the
conservatively treated patients needed signi®cantly more
blood transfusions (P  0:05).
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Table 1
Incidence of paravalvular leak in subgroups of patients with different
underlying diseases
Mitral valve
replacement
Paravalvular
leak
Incidence
(%)
Mitral valve replacement
reoperation
260 32 12.3
Mitral stenosis 84 10 11.9
Mitral valve prolapse 62 11 17.7
Combined mitral valve
disease
150 13 8.6
Ischaemic mitral valve
regurgitation
24 1 4.7
Endocarditis 29 12 41.4
Paravalvular leak
(`re-leak')
20 7 35
Fig. 2. Interval between mitral valve replacement and diagnosis of paravalvular leak.
The procedures carried out in the surgically treated group
included the reattachment of the prosthesis with interrupted
sutures in 30/50 patients (60%) and replacement of the
mitral prosthesis in 20/50 patients (40%). Re-leak after
surgical closure of the primary mitral paravalvular leak
was found in 11/50 patients (22%). No risk factors for the
development of a re-leak were identi®ed; four cases
occurred after reattachment and seven after mitral valve
replacement (P  0:74), this indicating no in¯uence of
surgical procedure.
4. Discussion
Despite an operative mortality of 6%, surgery offers
improved survival and a reduction in symptoms in patients
with paravalvular leak after mitral valve replacement. For
these reasons, surgery should be offered to less symptomatic
patients, as well as those not requiring blood transfusion.
The incidence of paravalvular leak after mitral valve
replacement was 12.5%; this does not include paravalvular
leaks identi®ed accurately at the time of surgery by intra-
operative transoesophageal echocardiography. This rate
corresponds to that reported by other authors [4±6]. Some
reports of lower rates are explainable by the selection of the
patients. For example, Dhasmana [5] reported an incidence
of 9.3%, but excluded all patients with endocarditis as the
underlying reason for mitral valve replacement. This is
especially notable, as endocarditis was associated with the
highest incidence of paravalvular leak in our study. The
development of a paravalvular leak in the early postopera-
tive period in a patient with infective endocarditis, or
sustained positive blood cultures despite adequate antibiotic
therapy, indicates a failure to control the infection [7]. In
these cases, prolonged antibiotic therapy is necessary
following diagnosis of the leak and prior to surgery.
However, the majority of late paravalvular leaks are not
associated with recurrent infection and can be repaired with-
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Table 2
Comparison of baseline data between surgically and conservatively treated
patients
P-value
Age ns
Gender ns
Size of leak ns
Localization of leak ns
Number of leaks ns
Atrial size ns
Fatigue ns
Vertigo ns
Interval between mitral valve replacement and diagnosis ns
Underlying disease ns
Coronary artery disease ns
Diabetes mellitus ns
Renal insuf®ciency ns
Calci®cation of the mitral valve annulus ns
NYHA class III/IV symptoms 0.029
Haematocrit 0.0016
LDH 0.0017
Fig. 3. Comparison of pre-operative NYHA functional status between surgical and conservative strategies.
Fig. 4. In¯uence of therapeutic strategy on survival.
out replacement of the valve. For example, in the Stanford
series [8], ®ve of six patients with late paravalvular leak had
an annular abscess at initial surgery.
Due to the very strictly controlled indication for
bioprosthesis in the mitral position in our institution [9],
we can not verify the statement of Hammermeister [10],
who reported a lower incidence of paravalvular leaks after
bioprosthesis in contrast to von Segesser [9]. Dhasmana [5]
also suggested that the use of a small mono®lament suture in
a continuous suture technique may be another contributory
factor in the development of a paravalvular leak. In all
cases, we used an interrupted pledgeted 2-0 Ticron mattress
suture technique.
The underlying disease of the mitral valve does not in¯u-
ence the interval between mitral valve replacement and
diagnosis of paravalvular leak. In our study, the median
interval of 119 days between replacement and diagnosis
was smaller than that reported in other publications. This
could be the consequence of accurate follow-ups by our
cardiologists at 3 months and 1 year postoperatively. It is
interesting to note the in¯uence of the age of the patient, the
size of the leak and extended hemolysis on this interval.
Paravalvular leaks are the most common reason for repeat
of mitral valve replacement surgery [7,11,12]. Amongst the
75 patients with paravalvular leaks after mitral valve repla-
cement performed at our institution between 1987 and 1997,
29 (39%) had surgical treatment.
Compared to Jindani [4], who reported a mortality rate of
22% following reoperation, our early mortality is markedly
lower and con®rmed the opinion of Syracuse [13], who
considered reoperation for paravalvular leaks to be a low-
risk operation. In our study, we can show that surgical stra-
tegies are associated with better survival than conservative
strategies. The baseline data at the time of diagnosis of the
paravalvular leak were comparable for the two groups, with
the exception of more NYHA class III/IV symptomatic
patients and more extended haemolysis in the surgical
group. The decision as to which treatment strategy the
patients received was made by the cardiologist. Surgery is
clearly indicated in patients requiring blood transfusion and
those with signs of heart failure [4]. Although there is nowa-
days widespread agreement among cardiologists and
surgeons alike that severe paravalvular leak should be
corrected immediately, the management of patients with
mild and moderate paravalvular leak is controversial.
Movsowitz [2] reported clinical deterioration over time in
some patients with moderate and mild leaks. The number
and size of the leaks was not a criterion for choosing a
surgical strategy. However, we saw that larger leaks resulted
in more dyspnoea and multiple leaks resulted in extended
hemolysis; thus, the characteristics of the leaks may have
indirectly in¯uenced the decision. Despite the fact that
surgically treated patients are at an overall higher risk, the
mortality rate in the follow-up period was signi®cantly
lower than in conservatively treated patients. The conse-
quence of this ®nding is that surgical treatment must also
be guaranteed in patients who are less symptomatic and in
those not requiring blood transfusion. Not only was the
mortality rate lower, but the symptoms were also reduced
to a lower level than seen in the conservatively treated
group. In addition, surgery decreased the need for blood
transfusion during the follow-up period.
Delay of surgery may increase the mortality rate. Indeed,
in the series of Jindani [4], the interval between mitral valve
replacement and diagnosis of the paravalvular leak was
longer, the number of patients with heart failure was higher
and the mortality rate was higher. Nevertheless, patients
undergoing reoperation of primary tissue failure of the pros-
thesis have been reported to have a better life expectancy
compared with those having reoperation because of para-
valvular leak, endocarditis or thrombosis [14].
The surgical procedures used comprised either reattach-
ment of the valve with single stitches or a mitral valve
replacement. In cases of intermediate and large paravalvular
leaks, valve replacement was preferred. We did not observe
any differences between these two procedures in terms of
symptoms, haemolysis or left ventricular function. The
choice of technique should therefore be surgeon-dependent.
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Appendix A. Conference discussion
Dr M. Antunes (Coimbra, Portugal): Weren't your results a little bit
skewed by the fact that there were indeed some patients who required blood
transfusions, for example, in the conservative group. If those patients had
been removed from the conservative group and treated surgically, would
not the differences be less evident?
Dr Genoni: The difference is that in the surgery we started our observa-
tion time at the time when the diagnosis of paravalvular leak was made.
Then we divided the patients in the surgical and in the conservative group.
So the patients in the conservative group have a follow-up time of 5 years,
and in these 5 years they receive blood transfusions.
Dr J. Bachet (Paris, France): Paravalvular leaks after surgery
obviously call the surgical technique into play. Could you give us some
details on how you implant the mitral valve and what kind of technique you
use? Do you use a continuous suture, interrupted suture, or pledgeted
sutures, etc?
Dr Genoni: All the primary mitral valve replacements were inserted
with an interrupted pledgeted suture technique.
Dr Antunes: It is interesting, because the incidence, which we know is
much larger than one usually believes, was 12.5%, and it is usually believed
that it is much less with interrupted sutures.
Dr Genoni: Yes, but I think the incidence is the same as reported in the
literature.
Dr Antunes: I am not arguing with that.
Dr Genoni: Because you ®nd only a few reports including all patients.
Dr R. Autschbach (Leipzig, Germany): Can you tell us something about
the valves you implanted and the sizes of these valves?
Dr Genoni: No, the sizes I don't know right now, but in 96% of our
patients we used mechanical valves and in 4% we used biological valves.
Dr H. Oelert (Mainz, Germany): When you closed the paravalvular
leak, was it always possible to close the leak or do you also have to rere-
place the valve? In our experience, especially if there is endocarditis as the
basic lesion, you should replace the valve instead of repairing a leak.
Dr Genoni: Well, the procedure carried out in the surgically treated
group was reattachment of the prosthesis in 30 out of 50 patients, which was
60%, and replacement in 40% of our patients. We observed in this retro-
spective study that patients with a small leak were mainly reattached, and
those with large and multiple leaks were subjected to replacements. The
patients with large leaks are also those that had endocarditis at primary
mitral valve replacement.
Dr Antunes: Were they still infected at the time of the closure of the
paravalvular leak? Could you correlate with that?
Dr Genoni: Only 10% of the patients with endocarditis had primary
mitral valve replacement.
Dr G. Rizzoli (Padova, Italy): I would like to know how your patients
were strati®ed between surgery and conservative treatment, and especially
what was the crossover rate of patients from the medical to the surgical
treatment? Also I would like to know why about 70% of your patients in the
third and fourth class have been operated on? What happened to the remain-
ing 30%?
Dr Genoni: The problems faced by patients is that they are examined by
cardiologists, and the cardiologists, in turn, have to decide whether to refer
the patients to surgeons. We only saw the patients in our retrospective
study. Our current policy is that we operate on all patients that are sympto-
matic, all patients with hemolysis. We only wait for the operation on
patients with a small leak, patients with solitary leaks and patients with
small left atria with normal pulmonary artery pressures. All other patients
will be operated on.
Dr F. Wellens (Aalst, Belgium): In this pathology, the challenge for the
cardiac surgeon is not the ®rst redo operation, it is the second or the third or
the fourth redo operation, leading to a very conservative approach in treat-
ing these patients to repair a recurrent leak. Application of Heartport tech-
nology for this very dif®cult subset of patients is excellent, just using the
Endoclamp and then making a normal right lateral thoracotomy gives
excellent results with very low mortality and morbidity in this dif®cult
subset of patients with recurrent paravalvular leaks.
Dr Antunes: Well, we mustn't forget that this was a retrospective study
and that you found what you found.
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